





an Open Access Journal by MDPI

Imaging Biomarkers in Oncology

Guest Editors:

Dr. Lorenzo Faggioni

Department of Translational Research, University of Pisa, 56126 Pisa, Italy

Prof. Dr. Dania Cioni

Department of Surgery, University of Pisa, 56126 Pisa, Italy

Dr. Michela Gabelloni

Department of Translational Research, University of Pisa, 56126 Pisa, Italy

Deadline for manuscript submissions:

30 June 2024

Message from the Guest Editors

Dear Colleagues,

In the last decade, oncology has seen dramatic advancements that have revolutionized cancer care. allowing for a more personalized treatment approach and overall improved patient management in an increasing proportion of clinical scenarios. In this context, medical imaging plays a key role in defining and evaluating specific imaging biomarkers, intended as objective imaging-based indicators that may serve to refine or enhance diagnostic information obtained by conventional image analysis, assess early therapeutic responses, predict individual outcomes, and guide treatment based on patient- and disease-specific features. The purpose of this Special Issue is to collect evidence from the latest research landscape regarding the status of imaging biomarkers in oncology, with a special focus on radiomics and its evolving role in the advanced management of the most common and paradigmatic cancers.

Dr. Lorenzo Faggioni Prof. Dr. Dania Cioni Dr. Michela Gabelloni *Guest Editors*













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

 Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
Division of Hematologic Malignancies and Cellular Therapy, Duke University,

Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us